229 related articles for article (PubMed ID: 2291654)
1. Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria.
Dutka-Malen S; Leclercq R; Coutant V; Duval J; Courvalin P
Antimicrob Agents Chemother; 1990 Oct; 34(10):1875-9. PubMed ID: 2291654
[TBL] [Abstract][Full Text] [Related]
2. Glycopeptide-resistant enterococci: a decade of experience.
Woodford N
J Med Microbiol; 1998 Oct; 47(10):849-62. PubMed ID: 9788808
[TBL] [Abstract][Full Text] [Related]
3. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Felmingham D; Brown DF; Soussy CJ
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
[TBL] [Abstract][Full Text] [Related]
4. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
[TBL] [Abstract][Full Text] [Related]
5. Resistance of enterococci to aminoglycosides and glycopeptides.
Leclercq R; Dutka-Malen S; Brisson-Noël A; Molinas C; Derlot E; Arthur M; Duval J; Courvalin P
Clin Infect Dis; 1992 Sep; 15(3):495-501. PubMed ID: 1520800
[TBL] [Abstract][Full Text] [Related]
6. Emergence of vancomycin-resistant enterococci in Australia: phenotypic and genotypic characteristics of isolates.
Bell JM; Paton JC; Turnidge J
J Clin Microbiol; 1998 Aug; 36(8):2187-90. PubMed ID: 9665988
[TBL] [Abstract][Full Text] [Related]
7. Genotypic characterization of a nosocomial outbreak of VanA Enterococcus faecalis.
Biavasco F; Miele A; Vignaroli C; Manso E; Lupidi R; Varaldo PE
Microb Drug Resist; 1996; 2(2):231-7. PubMed ID: 9158765
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.
Grüneberg RN; Hryniewicz W
Int J Antimicrob Agents; 1998 Nov; 10(4):271-7. PubMed ID: 9916900
[TBL] [Abstract][Full Text] [Related]
9. Occurrence and spread of antibiotic resistances in Enterococcus faecium.
Klare I; Konstabel C; Badstübner D; Werner G; Witte W
Int J Food Microbiol; 2003 Dec; 88(2-3):269-90. PubMed ID: 14597000
[TBL] [Abstract][Full Text] [Related]
10. Quality assessment of glycopeptide susceptibility tests: a European collaborative study. European Glycopeptide Resistance Group.
Brown DF; Courvalin P
Int J Antimicrob Agents; 1997 Jan; 9(3):153-63. PubMed ID: 9552711
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms and implications of glycopeptide resistance in enterococci.
Derlot E; Courvalin P
Am J Med; 1991 Sep; 91(3B):82S-85S. PubMed ID: 1656750
[TBL] [Abstract][Full Text] [Related]
12. Resistance to vancomycin and teicoplanin: an emerging clinical problem.
Johnson AP; Uttley AH; Woodford N; George RC
Clin Microbiol Rev; 1990 Jul; 3(3):280-91. PubMed ID: 2143434
[TBL] [Abstract][Full Text] [Related]
13. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
14. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
[TBL] [Abstract][Full Text] [Related]
15. Significant increase in the isolation of glycopeptide-resistant enterococci from patients hospitalized in the transplant surgery ward in 2004-2005.
Młynarczyk G; Grzybowska W; Młynarczyk A; Tyski S; Kawecki D; Łuczak M; Chmura A; Rowiński W
Transplant Proc; 2007 Nov; 39(9):2883-5. PubMed ID: 18022008
[TBL] [Abstract][Full Text] [Related]
16. In vitro conjugative transfer of VanA vancomycin resistance between Enterococci and Listeriae of different species.
Biavasco F; Giovanetti E; Miele A; Vignaroli C; Facinelli B; Varaldo PE
Eur J Clin Microbiol Infect Dis; 1996 Jan; 15(1):50-9. PubMed ID: 8641304
[TBL] [Abstract][Full Text] [Related]
17. Characterization of glycopeptide-resistant enterococci from U.S. hospitals.
Clark NC; Cooksey RC; Hill BC; Swenson JM; Tenover FC
Antimicrob Agents Chemother; 1993 Nov; 37(11):2311-7. PubMed ID: 8285611
[TBL] [Abstract][Full Text] [Related]
18. Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies.
Jones ME; Gesu G; Ortisi G; Sahm DF; Critchley IA; Goglio A;
Clin Microbiol Infect; 2002 Feb; 8(2):101-11. PubMed ID: 11952723
[TBL] [Abstract][Full Text] [Related]
19. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium.
Leclercq R; Derlot E; Weber M; Duval J; Courvalin P
Antimicrob Agents Chemother; 1989 Jan; 33(1):10-5. PubMed ID: 2523687
[TBL] [Abstract][Full Text] [Related]
20. First Report of the Local Spread of Vancomycin-Resistant Enterococci Ascribed to the Interspecies Transmission of a
Hashimoto Y; Kita I; Suzuki M; Hirakawa H; Ohtaki H; Tomita H
mSphere; 2020 Apr; 5(2):. PubMed ID: 32269153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
